| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eli Lilly and Company |
| Information provided by: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT00034463 |
Purpose
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
| Condition | Intervention | Phase |
|
Metastases Cancer |
Drug: ALIMTA Drug: folic acid Drug: multi-vitamins |
Phase I |
| MedlinePlus related topics: | Cancer |
| Drug Information available for: | Pemetrexed disodium Pemetrexed Folic acid |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Texas | |||||
| For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. | |||||
| San Antonio, Texas, United States | |||||
| Eli Lilly and Company |
More Information
| Study ID Numbers: | 1310, H3E-MC-JMAS |
| First Received: | April 29, 2002 |
| Last Updated: | July 18, 2006 |
| ClinicalTrials.gov Identifier: | NCT00034463 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
